Literature DB >> 15367603

Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels.

Anthony Sanchez1, Matthew Lukwiya, Daniel Bausch, Siddhartha Mahanty, Angela J Sanchez, Kent D Wagoner, Pierre E Rollin.   

Abstract

Peripheral blood samples obtained from patients during an outbreak of Ebola virus (Sudan species) disease in Uganda in 2000 were used to phenotype peripheral blood mononuclear cells (PBMC), quantitate gene expression, measure antigenemia, and determine nitric oxide levels. It was determined that as the severity of disease increased in infected patients, there was a corresponding increase in antigenemia and leukopenia. Blood smears revealed thrombocytopenia, a left shift in neutrophils (in some cases degenerating), and atypical lymphocytes. Infected patients who died had reduced numbers of T cells, CD8(+) T cells, and activated (HLA-DR(+)) CD8(+) T cells, while the opposite was noted for patients who survived the disease. Expression levels of cytokines, Fas antigen, and Fas ligand (TaqMan quantitation) in PBMC from infected patients were not significantly different from those in uninfected patients (treated in the same isolation wards), nor was there a significant increase in expression compared to healthy volunteers (United States). This unresponsive state of PBMC from infected patients despite high levels of circulating antigen and virus replication suggests that some form of immunosuppression had developed. Ebola virus RNA levels (virus load) in PBMC specimens were found to be much higher in infected patients who died than patients who survived the disease. Similarly, blood levels of nitric oxide were much higher in fatal cases (increasing with disease severity), and extremely elevated levels (>/=150 microM) would have negatively affected vascular tone and contributed to virus-induced shock.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367603      PMCID: PMC516433          DOI: 10.1128/JVI.78.19.10370-10377.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

Review 1.  Nitric oxide and infectious diseases.

Authors:  D Burgner; K Rockett; D Kwiatkowski
Journal:  Arch Dis Child       Date:  1999-08       Impact factor: 3.791

2.  Regulatory function of in vivo anergized CD4(+) T cells.

Authors:  K Jooss; B Gjata; O Danos; H von Boehmer; A Sarukhan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

3.  Diversity of endotoxin-induced nitrotyrosine formation in macrophage-endothelium-rich organs.

Authors:  K Bian; F Murad
Journal:  Free Radic Biol Med       Date:  2001-08-15       Impact factor: 7.376

4.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

5.  Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro.

Authors:  M Gupta; S Mahanty; R Ahmed; P E Rollin
Journal:  Virology       Date:  2001-05-25       Impact factor: 3.616

6.  Multiplex analysis of cytokines in the blood of cynomolgus macaques naturally infected with Ebola virus (Reston serotype).

Authors:  K L Hutchinson; F Villinger; M E Miranda; T G Ksiazek; C J Peters; P E Rollin
Journal:  J Med Virol       Date:  2001-11       Impact factor: 2.327

7.  Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125-kDa GP viral protein.

Authors:  A A Chepurnov; M N Tuzova; V A Ternovoy; I V Chernukhin
Journal:  Immunol Lett       Date:  1999-06-01       Impact factor: 3.685

8.  Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system?

Authors:  S Baize; E M Leroy; E Mavoungou; S P Fisher-Hoch
Journal:  Apoptosis       Date:  2000-02       Impact factor: 4.677

9.  NOX 100, a nitric oxide scavenger, enhances cardiac allograft survival and promotes long-term graft acceptance.

Authors:  A M Roza; M Cooper; G Pieper; G Hilton; K Dembny; C S Lai; P Lindholm; R Komorowski; C Felix; C Johnson; M Adams
Journal:  Transplantation       Date:  2000-01-27       Impact factor: 4.939

10.  Nitric oxide and chronic HCV and HIV infections.

Authors:  G Lake-Bakaar; D Sorbi; V Mazzoccoli
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.487

View more
  115 in total

1.  Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus.

Authors:  Hideki Ebihara; Barry Rockx; Andrea Marzi; Friederike Feldmann; Elaine Haddock; Douglas Brining; Rachel A LaCasse; Don Gardner; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

2.  Robust and sustained immune activation in human Ebola virus infection.

Authors:  Judith N Mandl; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-07       Impact factor: 11.205

3.  Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.

Authors:  John C Kash; Kathie-Anne Walters; Jason Kindrachuk; David Baxter; Kelsey Scherler; Krisztina B Janosko; Rick D Adams; Andrew S Herbert; Rebekah M James; Spencer W Stonier; Matthew J Memoli; John M Dye; Richard T Davey; Daniel S Chertow; Jeffery K Taubenberger
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

4.  Using a field quantitative real-time PCR test to rapidly identify highly viremic rift valley fever cases.

Authors:  M Kariuki Njenga; Janusz Paweska; Rose Wanjala; Carol Y Rao; Matthew Weiner; Victor Omballa; Elizabeth T Luman; David Mutonga; Shanaaz Sharif; Marcus Panning; Christian Drosten; Daniel R Feikin; Robert F Breiman
Journal:  J Clin Microbiol       Date:  2009-01-26       Impact factor: 5.948

5.  Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease.

Authors:  Anita K McElroy; Jessica R Harmon; Timothy D Flietstra; Shelley Campbell; Aneesh K Mehta; Colleen S Kraft; Marshall G Lyon; Jay B Varkey; Bruce S Ribner; Christopher J Kratochvil; Peter C Iwen; Philip W Smith; Rafi Ahmed; Stuart T Nichol; Christina F Spiropoulou
Journal:  Clin Infect Dis       Date:  2016-06-27       Impact factor: 9.079

6.  Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression.

Authors:  Christopher R Kimberlin; Zachary A Bornholdt; Sheng Li; Virgil L Woods; Ian J MacRae; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

7.  Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome.

Authors:  Anita K McElroy; Bobbie R Erickson; Timothy D Flietstra; Pierre E Rollin; Stuart T Nichol; Jonathan S Towner; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2014-02-12       Impact factor: 5.226

8.  Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition.

Authors:  Osvaldo Martinez; Joshua Johnson; Balaji Manicassamy; Lijun Rong; Gene G Olinger; Lisa E Hensley; Christopher F Basler
Journal:  Cell Microbiol       Date:  2009-09-22       Impact factor: 3.715

9.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

10.  The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains.

Authors:  Ndongala M Lubaki; Philipp Ilinykh; Colette Pietzsch; Bersabeh Tigabu; Alexander N Freiberg; Richard A Koup; Alexander Bukreyev
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.